BAXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BAXTER INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$24.99−0.29 (-1.15%)
Close on Oct 19, 2026
- Market cap
- $12.94B
- P/E (TTM)
- –
- Dividend yield
- 2.08%
BAXTER INTERNATIONAL INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Products & Therapies | $5.30B | $5.21B | $5.01B | $4.82B | $4.82B | – | – | – | – | – | 47.1% | +1.8% |
| Healthcare Systems & Technologies | $3.07B | $2.95B | $3.01B | $2.94B | $212.00M | – | – | – | – | – | 27.3% | +4.1% |
| Pharmaceuticals | $2.49B | $2.41B | $2.25B | $2.13B | $2.29B | – | – | – | – | – | 22.2% | +3.4% |
| EMEA | – | – | – | – | – | – | – | – | $2.73B | $2.70B | – | – |
| APAC | – | – | – | – | – | – | $2.30B | $2.20B | $2.11B | $2.03B | – | – |
| Americas | – | – | – | – | – | – | $6.09B | $5.95B | $5.72B | $5.44B | – | – |
| EMEA | – | – | – | – | – | – | $2.97B | $2.95B | $2.75B | $2.70B | – | – |
| APAC | – | – | – | $2.59B | $2.79B | $2.48B | $2.30B | $2.20B | – | – | – | – |
| Americas | – | – | – | $6.71B | $6.67B | $6.32B | $6.31B | $5.95B | – | – | – | – |
| EMEA | – | – | – | $2.88B | $3.12B | $2.88B | $2.76B | $2.95B | – | – | – | – |
| Hillrom | – | – | – | $2.94B | $212.00M | $0 | $0 | – | – | – | – | – |
| Kidney Care | – | – | $4.45B | $4.45B | $4.68B | – | – | – | – | – | – | – |
| Renal Care | – | – | – | – | – | – | – | – | – | $3.86B | – | – |
| Hospital Products | – | – | – | – | – | – | – | – | – | $6.31B | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Products & Therapies | $970.00M | $950.00M | $972.00M | $962.00M | $955.00M | – | – | – | – | – | +2.1% |
| Healthcare Systems & Technologies | $441.00M | $468.00M | $483.00M | $494.00M | $60.00M | – | – | – | – | – | -5.8% |
| Pharmaceuticals | $222.00M | $313.00M | $401.00M | $391.00M | $523.00M | – | – | – | – | – | -29.1% |
| Reportable Segment | -$308.00M | $14.00M | $707.00M | -$2.85B | – | – | – | – | – | – | -2300.0% |
| EMEA | – | – | – | – | – | – | – | – | $564.00M | $476.00M | – |
| APAC | – | – | – | – | – | – | $549.00M | $532.00M | $510.00M | $464.00M | – |
| Americas | – | – | – | – | – | – | $2.37B | $2.41B | $2.24B | $2.08B | – |
| EMEA | – | – | – | – | – | – | $652.00M | $666.00M | $562.00M | $476.00M | – |
| APAC | – | – | – | $623.00M | $623.00M | $591.00M | $549.00M | $532.00M | – | – | – |
| Americas | – | – | – | $2.38B | $2.61B | $2.39B | $2.50B | $2.41B | – | – | – |
| EMEA | – | – | – | $607.00M | $632.00M | $523.00M | $527.00M | $666.00M | – | – | – |
| Hillrom | – | – | – | $730.00M | -$80.00M | $0 | $0 | – | – | – | – |
| Other | – | – | $18.00M | $77.00M | $59.00M | – | – | – | – | – | – |
| Kidney Care | – | – | $300.00M | $408.00M | $488.00M | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renal Care | – | – | – | – | – | – | – | $3.66B | $3.48B | $3.42B | – | – |
| Acute Therapies | – | – | – | – | – | – | – | $517.00M | $456.00M | $429.00M | – | – |
| Medication Delivery | – | – | – | $2.89B | $2.88B | $2.69B | $2.74B | $2.66B | $2.70B | $2.60B | – | – |
| Pharmaceuticals | – | – | – | $2.13B | $2.29B | $2.10B | $2.12B | $2.09B | $1.89B | $1.72B | – | – |
| Nutrition | – | – | – | – | – | – | – | – | $882.00M | $858.00M | – | – |
| Advanced Surgery | – | – | – | $998.00M | $977.00M | $886.00M | $875.00M | $798.00M | $708.00M | $690.00M | – | – |
| Other | – | – | – | $140.00M | $109.00M | $105.00M | $126.00M | $509.00M | $457.00M | $447.00M | – | – |
| Clinical Nutrition | – | – | – | $931.00M | $964.00M | $910.00M | $860.00M | $875.00M | $885.00M | $858.00M | – | – |
| Acute Therapies | – | – | – | $701.00M | $782.00M | $740.00M | $535.00M | $515.00M | $457.00M | – | – | – |
| Renal Care | – | – | – | $3.75B | $3.90B | $3.76B | $3.64B | $3.65B | $3.49B | – | – | – |
| BioPharma Solutions | – | – | – | $644.00M | $669.00M | $486.00M | $469.00M | – | – | – | – | – |
| Surgical Solutions | – | – | – | $304.00M | $27.00M | $0 | $0 | – | – | – | – | – |
| Front Line Care | – | – | – | $1.15B | $70.00M | $0 | $0 | – | – | – | – | – |
| Patient Support Systems | – | – | – | $1.49B | $115.00M | $0 | $0 | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $6.12B | $5.85B | $5.80B | $5.77B | $4.94B | $4.88B | $4.83B | $4.72B | $4.51B | $4.26B | 54.4% | +4.6% |
| International | $5.12B | $4.79B | $4.56B | $4.29B | $7.21B | $6.80B | $6.54B | $6.38B | $6.07B | – | 45.6% | +7.0% |
| Rest of world | $3.73B | $3.44B | $3.22B | $3.04B | $4.20B | – | – | – | – | – | 33.2% | +8.5% |
| Emerging markets | $1.39B | $1.35B | $1.34B | $1.25B | $3.01B | – | – | – | – | – | 12.4% | +3.3% |
| APAC | – | – | – | $2.75B | $2.80B | $2.48B | $2.30B | $2.20B | $2.11B | $2.03B | – | – |
| Europe | – | – | – | – | – | – | – | – | $2.73B | $2.70B | – | – |
| Latin America and Canada | – | – | – | $1.43B | $1.25B | $1.19B | $1.27B | $1.23B | $1.21B | $1.18B | – | – |
| Americas | – | – | – | – | – | $6.07B | $6.09B | $5.95B | $5.72B | $5.44B | – | – |
| EMEA | – | – | – | $3.71B | $3.55B | $3.13B | $2.97B | $2.95B | $2.75B | $2.70B | – | – |
From the segment and revenue-disaggregation notes of Baxter International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.